Sulzyc-Bielicka Violetta, Bińczak-Kuleta Agnieszka, Pioch Wiesława, Kładny Józef, Gziut Katarzyna, Bielicki Dariusz, Ciechanowicz Andrzej
Department of Oncological Surgery, Pomeranian Medical University, Powstańców Wlkp. 72, PL 70-111 Szczecin, Poznań, Poland.
Pharmacol Rep. 2008 Mar-Apr;60(2):238-42.
DPYD gene encodes dihydropyrimidine dehydrogenase which is the initial and rate-limiting enzyme in the metabolism of 5-fluorouracil (5-FU). The aim of our study was PCR-RFLP based-genetic testing for the most common 5-FU toxicity-attributable IVS14 + 1G > A DPYD mutation (DPYD()2A) in 252 Polish colorectal cancer (CRC) patients treated with this adjuvant chemotherapeutic regimen after surgery. The DPYD()2A allele was identified only in one patient: a male who was one of 4 CRC patients suffering from grades 3-4 myelotoxicity upon 5-FU chemotherapy. We conclude that IVS14 + 1G > A DPYD (DPYD(*)2A) variant occurs in the Polish population and is responsible for a significant proportion of life-threatening toxicity of 5-FU.
DPYD基因编码二氢嘧啶脱氢酶,它是5-氟尿嘧啶(5-FU)代谢过程中的起始和限速酶。我们研究的目的是对252例接受术后这种辅助化疗方案治疗的波兰结直肠癌(CRC)患者进行基于PCR-RFLP的基因检测,以检测最常见的与5-FU毒性相关的IVS14 + 1G>A DPYD突变(DPYD()2A)。仅在一名患者中鉴定出DPYD()2A等位基因:该男性是4例在5-FU化疗后出现3-4级骨髓毒性的CRC患者之一。我们得出结论,IVS14 + 1G>A DPYD(DPYD(*)2A)变体在波兰人群中出现,并且是5-FU严重危及生命毒性的重要原因。